Investigation of therapeutic potential of plant-derived nanovesicles in mitochondrial dysfunction of skin cells under psoriasis-like inflammation

Introduction Psoriasis is a chronic inflammatory skin disease characterized by immune system dysregulation and epidermal hyperproliferation (1), however, the roles of mitochondria in psoriasis pathogenesis are poorly understood. Key cytokines creating a psoriatic environment are tumor necrosis factor (TNF)-α, interleukin (IL)-17A, and IL-22 (2). Biological agents acting systemically on psoriasis-related cytokines are considered the most advanced treatment for psoriasis. However, biological therapies show variability in response among individuals, and can lead to severe side effects (3). Plant-derived nanovesicles (PDNVs) offer therapeutic potential due to their ability to deliver various active molecules to recipient cells (4), however, their impact on mitochondrial function in psoriatic keratinocytes and fibroblasts, key players in psoriasis, is unclear. This work aimed to investigate metabolic response and mitochondrial network morphology in keratinocytes and fibroblasts under psoriasis-like inflammation. Additionally, we aimed to test how Melissa Officinalis-derived nanovesicles (NVs) affect the mitochondrial function of these cells. [...].